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Introduction
Species in the Atractaspis genus within the Lamprophiidae snake family are nocturnal burrowing venomous snakes (Spawls and Branch, 1995) . This genus represents the third independent evolution of frontfangs within snakes . Their fangs erect on a horizontal plane rather than on a vertical plane like in viperids, resulting in descriptive common names including switchblade snakes and stiletto snakes. Bites are characterized by strong, local pain accompanied by swelling and localized tissue necrosis (amputation resulting in some survivors), coagulation disturbances including elevated partial thromboplastin time and decreased prothrombin index, rapid and severe hypertension, and deaths have been recorded (Coppola and Hogan, 1992; Kochva, 1998; Kurnik et al., 1999; Lee et al., 1986; Leisewitz et al., 2004; Tilbury and Verster, 2016) .
Despite their evolutionary novelty and documented severe envenomation effects, their venom is underinvestigated relative to the intensive efforts on elapid and viperid snake venoms. Work to-date has largely focused on the endothelin-type peptides called sarafotoxins which are responsible for the dramatic rise in blood pressure observed clinically (Abd-Elsalam, 2011; Atkins et al., 1995; Borgheresi et al., 2001; Goyffon, 1994; Ismail et al., 2007; Kawanabe and Nauli, 2011; Kolb, 1991; Mahjoub et al., 2015; Malaquin et al., 2016; Nakajima et al., 1989; Nayler et al., 1989; Patocka et al., 2004; Takasaki et al., 1992; Tilbury and Verster, 2016; Warrell et al., 1976) . The only other characterized toxin type from Atractaspis venom has been a hemorrhagic metalloprotease (Ovadia, 1987) . Transcriptome sequencing has shown that toxin types present in the venom include peptides (three finger, AVIT, beta-defensin, c-type lectin, cystatin, sarafotoxin, waprin), non-enzymatic proteins (CRiSP, lipocalin, nerve growth factor) and enzymes (acetylcholinesterase, kallikrein-type serine protease, metalloprotease, phospholipase A 2 ) (Terrat et al., 2013) .
In snake venoms, procoagulant toxin types include metalloproteases Debono et al., 2017; Rogalski et al., 2017) , kallikrein-type serine proteases (Vaiyapuri et al., 2015) and mutant forms of the blood factors FXa and FVa which are specifically expressed in venom glands (Cipriani et al., 2017; Earl et al., 2015; Lister et al., 2017; Trabi et al., 2015) . Procoagulant functions produce endogenous thrombin by Factor V activation (Vaiyapuri et al., 2015) , Factor VII activation (Cipriani et al., 2017) , Factor X activation Vaiyapuri et al., 2015) and prothrombin activation Rogalski et al., 2017; Trabi et al., 2015) . The endogenous thrombin in turn cleaves fibrinogen to form normal, well cross-linked, and strong clots. Procoagulant functions may be accompanied by synergistic functions such as Factor XIII activation by kallikrein-type serine proteases to further cross-link the fibrin mesh (Vaiyapuri et al., 2015) , and plasmin inhibition by kunitz peptides to prevent plasmin from degrading the clots (Eng et al., 2015) . This aids in prey subjugation through the rapid induction of stroke, while conversely in human victims the venom is diluted into a much larger blood volume resulting in defibrinogenation, with death due to internal bleeding such as cerebral hemorrhage Herrera et al., 2012; Jackson et al., 2016) .
Anticoagulant functions in snake venoms occur in two forms: pseudo-procoagulant functions in which a part of the clotting cascade is catalyzed to produce unstable, weak clots which are readily broken down; and true anticoagulant functions in which clot formation is directly impeded. The pseudo-procoagulant action involves the atypical cleavage of fibrinogen by apotypic kallikrein-type serine proteases (Vaiyapuri et al., 2015) to form poorly cross-linked clots with short half-lives, leading to a net anticoagulant state Hutton and Warrell, 1993) . In contrast, true anticoagulant kallikrein-type serine proteases or metalloproteases cleave fibrinogen in a destructive, non-clotting manner that not only directly depletes the amount of fibrinogen available for clot formation, but the fibrinogen degradation products may also be bound by thrombin and thus also reduce the amount of thrombin available for clot formation Vaiyapuri et al., 2015) .
Both pseudo-procoagulant and anticoagulant functions may be accompanied by a myriad of synergistic functions including: alpha-2 antiplasmin blockage by kallikrein-type serine proteases (Vaiyapuri et al., 2015) ; antithromboplastic effects to prevent the formation of the prothrombinase complex by Group II PLA 2 (Sunagar et al., 2015b) ; Factor V denaturation by kallikrein-type serine proteases (Vaiyapuri et al., 2015) ; inhibition of the enzymatic activity of Factor VIIa and the Factor VIIa/tissue factor complex by three finger toxins (Utkin et al., 2015) ; Factor Xa inhibition by kunitz peptides (Eng et al., 2015) ; plasminogen activation by kallikrein-type serine proteases (Vaiyapuri et al., 2015) ; plasminogen activator release from endothelial cells by vascular permeability by kallikrein-type serine proteases and metalloproteases Vaiyapuri et al., 2015) ; platelet inhibition through receptor binding by disintegrins (separately and coupled to metalloproteases); Group I and Group II PLA 2 , lectins and three finger toxins (Arlinghaus et al., 2015; Casewell et al., 2015; Sunagar et al., 2015a,b; Utkin et al., 2015) ; protein C activation by kallikrein-type serine proteases (Vaiyapuri et al., 2015) ; thrombin inhibition by kunitz peptides (Eng et al., 2015) ; and blood vessel wall degradation by kallikrein-type serine proteases and metalloproteases Vaiyapuri et al., 2015) . Both pseudo-procoagulant and anticoagulant functions promote haemorrhagic shock, whether in prey or human victims (Boyer et al., 2015) .
Although coagulotoxic effects are suggested by the scarce clinical reports of Atractaspis envenomations, no laboratory studies have been undertaken to elucidate these effects. This study aims to fill these knowledge gaps by subjecting the venoms to a battery of assays to determine the nature and potency of effects upon the clotting cascade. We examined the three broad mechanisms of coagulotoxicity: procoagulant functions leading to thrombin production; pseudo-procoagulant functions upon fibrinogen with net anticoagulant outcomes; or true anticoagulant functions upon fibrinogen.
Materials and methods

Venoms examined
This study examined six Atractaspis specimens from five African countries in order to ascertain the nature and potency of coagulotoxic functions and the relative inhibition by available antivenoms. Specimen codes, species designation (as concluded by venom suppliers) and confirmed geographic origin were as follows: SP01 A. irregularis Congo; SP02 A. bibroni Tanzania; SP03 A. atterima Ghana; SP04 A. fallax Kenya; SP05 A. bibroni Tanzania; and SP06 A. irregularis Cameroon.
Coagulation analyses and relative antivenom efficacy
Coagulation analyses and relative antivenom efficacy studies were conducted as previously described by us Lister et al., 2017; Rogalski et al., 2017) . Coagulation analyses were performed on a Stago STA-R Max ® automated coagulation analyser (Stago, Asnières sur Seine, France) using Stago Analyser software v0.00.04 (Stago, Asnières sur Seine, France). All experiments were conducted in triplicate, with plasma and venom being replaced every 15-30 min to minimise enzyme degradation.
To check the quality of the plasma (Australian Red Cross research approval #16-04QLD-10; 44 Musk Street, Kelvin Grove, Queensland 4059), positive and negative controls were conducted and compared to pre-established plasma clotting parameters in the presence and absence of an activator (49-51 sec (s) and 526-586 s respectively). The positive control was conducted by performing a standardised activated Partial Thromboplastin Time (aPTT) test (Stago Cat#T1203 TriniCLOT APTT HS). In this test, 50 μl Kaolin (STA C.K.Prest standard kit, Stago Cat#00597), a coagulation activator, was added to 50 μl plasma and incubated for 120 s. Then, 50 μl CaCl 2 (0.025 M, Stago Cat#00367) was added, and time until clot formation was measured. As a negative control, test conditions in the absence of venom were replicated: 50 μl buffer solution (30 μl 50% deionised H 2 O/50% glycerol in 270 μl Owren-Koller (OK) buffer) was added to 50 μl CaCl 2 , 50 μl phospholipid and 25 μl OK buffer, and then incubated for 120 s at 37°C. 75 μl plasma was then added and clotting time measured. Both controls were run in triplicate before commencing any venom analyses.
In order to determine clotting times effected by the addition of varying venom concentrations, venom working stock solution was manually diluted with Owren Koller (OK) Buffer (Stago Cat# 00360) as appropriate in order to perform 10-point dilution series (μg/ml: 20, 10, 5, 2.5, 1.33, 0.66, 0.4, 0.2, 0.1, and 0.05). 50 μl of CaCl 2 with 50 μl phospholipid (cephalin prepared from rabbit cerebral tissue from STA C.K Prest standard kit, Stago Cat# 00597, solubilised in OK Buffer) were added to 50 μl of the diluted venom. An additional 25 μl of OK Buffer was added to the cuvette and incubated for 120 s at 37°C before adding 75 μl human plasma (total volume 250 μl/cuvette). Time until clot formation was then immediately monitored by the automated analyser.
In order to test for co-factor dependence of the venoms, the aforementioned coagulation analyses were run both with and without CaCl 2 and/or phospholipid. The experimental protocol was identical, with the exception that 50 μl OK Buffer was added as a substitute for the removed co-factor to ensure consistency in final test volumes (250 μl).
The relative efficacy of polyvalent and monovalent antivenoms were investigated in this study. The previously measured whole plasma clotting times for each venom were used as a baseline comparison for Coagulation times (sec) for each of the venoms and antivenoms were graphed using Prism 7.0 software (GraphPad Software Inc, La Jolla, CA, USA) to produce concentration response curves. Calculation of EC 50 (concentration of venom at which 50% of the effect is observed) values for the venom and antivenom concentration curves for each dataset were performed using Prism 7.0 software. Data are expressed as mean ± SD. After EC 50 s were calculated, the relative antivenom efficacy as indicated by x-fold shift in the clotting curve was calculated using the formula: Values 'c' and 'f' account for the initial shift in clotting time observed for the highest venom concentration (20 μg/ml) when comparing conditions in the presence vs. the absence of antivenom. Subtraction of '1' transforms the calculated ratio into a value representing the x-fold shift of the clotting curves following antivenom addition. For example, if there is no shift of the antivenom curve compared to venom curve (ie. the numerator divided by the denominator), then the parenthetical value would equal one, and one minus one would result in a zero-shift value for antivenom efficacy.
Calibrated automated thromography (CAT)
Calibrated automated thrombography studies were conducted as previously described by us . Thrombin generation was measured by a Calibrated Automated Thrombogram (CAT, Stago), using the method previously described by Hemker (Hemker, 2005; Hemker et al., 2003 Hemker et al., , 2002 . The following was pipetted into a 96-well round-bottom microtiter plate (Thermo Fisher Scientific, Waltham, Massachusetts, USA): a starting volume of 80 μl of pre-warmed human plasma (37°C), 10 μl of venom, and 10 μl of phospholipid. The plate was then inserted into a Thermo Fisher Fluoroskan fluorometer (Thermo Labsystem, Helsinki, Finland). The default 10-min incubation step was removed so as to capture the initial thrombin formation. Prior to starting, dispensing lines were washed and then primed with prewarmed 2.5 mmol/l fluorogenic substrate in 5 mmol/l CaCl2 (FluCaKit; Diagnostica Stago). The test was then automatically initiated by dispensing 20 μl of the fluorogenic substrate into each well and run at 37°C for 60-min, with readings automatically taken every 20 s. For each test, venom was added to an enzymatic buffer (150 mM NaCl & 50 mM Tris-HCL, pH 7.4) and manually pipetted into the wells for final concentrations of 0.083 μg/ml. Tests were performed in triplicate for each experiment with three calibrators per half plate. Calibrators adjusted for any internal filter effects and eliminated any variation in plasmas. For the calibrator assays, phospholipid and a venom trigger was substituted with a thrombin-α2-macroglobulin complex solution of a known concentration (thrombin calibrator, Stago, US). For each thrombin generation measurement, the following parameters were recorded by the Thrombinoscope software (Maastricht, The Netherlands): the endogenous thrombin potential (ETP), represented by the activity of free thrombin multiplied by the time it remains active in the plasma (area under the curve); maximum concentration of thrombin (peak); and lag-time (time to start). The RAW data was then converted by the Thrombinoscope software into thrombin activity (nM) corresponding to the calibrator (Hemker, 2005; Hemker et al., 2003 Hemker et al., , 2002 .
Zymogen activation: Factor X and prothrombin
To determine the relative rate of Factor X activation by the venom samples, the following were added into each well using a 384-well plate (black, Lot#1171125, nunc™ Thermo Scientific, Rochester, NY, USA) and performed in triplicate per venom: 10 μl of 0.001 μg/μl venom, 10 μl of 0.01 μg/μl human Factor X zymogen (Haematologic Technologies Inc. HCP-0050), and 10 μl each of CaCl 2 (0.025 M, Stago Catalog # 00367) and phospholipid (cephalin prepared from rabbit cerebral tissue adapted from STA C.K Prest standard kit, Stago Catalog # 00597), solubilised in 5 ml of OK Buffer (STA Owren Koller Buffer (Stago Cat# 00360)). Immediately thereafter, 60 μl of quenched fluorescent substrate was automatically dispensed per well (total volume of 100 μl in the well; 20 μl/5 ml OK buffer) using the following substrate: ES011 (Boc-Val-Pro-Arg-AMC. Boc: t-Butyloxycarbonyl; 7-Amino-4-methylcoumarin) (Lot #: NZY08, www.rndsystems.com). The hydrolysis reaction was monitored via fluorescence at 320/405 nm (excitation/emission). The amount of fluorescence was measured every 10 s for a total of 400 min. The machine was programmed to shake the plate for three sec before each reading to maintain homogeneity in the wells, and the plate was warmed in the machine to 37°C to mimic the human body. Human Factor Xa enzyme (0.01 μg/μl) (7.5 mg/ml HCXA -OO60 -R & D systems) was used as positive control to ensure functionality of the substrate. Human Factor X (0.01 μg/μl) was used as a negative control to ensure it did not directly cleave the substrate without the presence of venom.
Thromboelastography
Clot strength assays were conducted using a Thromboelastograph (TEG5000) using 3.2% citrated human plasma or 4 mg/ml human fibrinogen. 72 μl of 0.025 M CaCl 2 to reverse citration (Stago catalog# 00367), 72 μl phospholipid from the STA CK Prest (Stago catolog# 00597), 20 μl of μl OK buffer, and 7 μl 1 μg/μl crude venom were added before 189 μl plasma or fibrinogen were added and the test immediately started. Results were obtained for 30 min. If no clot was formed, 7 ul of thrombin from the Stago Liquid Fib Kit (Stago catalog# 00673) was added in order to perform a Claussian test (Clauss, 1957) 
Cleavage of fibrinogen
Fibrinogen cleavage studies were conducted as previously described by us Koludarov et al., 2017) . 1 mm 12% SDS-PAGE gels were prepared using the following recipe for the resolving gel layer: 3.3 ml deionised H 2 O, 2.5 ml 1.5 M Tris-HCl buffer pH 8.8 (Tris -Sigma-Aldrich, St. Louis, MO, USA; HCl -Univar, Wilnecote, UK), 100 μl 10% SDS (Sigma-Aldrich, St. Louis, MO, USA), 4 ml 30% acrylamide mix (Bio-Rad, Hercules, CA, USA), 100 μl 10% APS (BioRad, Hercules, CA, USA), 4 μl TEMED (Bio-Rad, Hercules, CA, USA); and stacking gel layer: 1.4 ml deionised H 2 O, 250 μl 0.5 M Tris-HCl buffer pH 6.8, 20 μl 10% SDS (Sigma-Aldrich, St. Louis, MO, USA), 330 ml 30% acrylamide mix (Bio-Rad, Hercules, CA, USA), 20 μl 10% APS (Bio-Rad, Hercules, CA, USA), 2 μl TEMED (Bio-Rad, Hercules, CA, USA). 10× gel running buffer was prepared using the following recipe: 250 mM Tris (Sigma-Aldrich, St. Louis, MO, USA), 1.92 M glycine (MP Biomedicals), 1% SDS (Sigma-Aldrich, St. Louis, MO, USA), pH 8.3.
Human fibrinogen was reconstituted to a concentration of 2 mg/ml in isotonic saline solution, flash-frozen in liquid nitrogen and stored at −80°C until use. Freeze-dried venom was reconstituted in deionised H 2 O and concentrations were measured using a Thermo Scientific™ NanoDrop 2000. Assay concentrations were a 1:10 ratio of venom:fibrinogen. The following was conducted in triplicate for each venom: Five "secondary" aliquots containing 10 μl buffer (5 μl of 4× Laemmli sample buffer (Bio-Rad, Hercules, CA, USA), 5 μl deionised H 2 O, 100 mM DTT (Sigma-Aldrich, St. Louis, MO, USA)) were prepared. A "primary" aliquot of fibrinogen (volume/concentration as per the above) was warmed to 37°C in an incubator. 10 μl was removed from the primary aliquot ("0 min incubation" fibrinogen control) and added to a secondary aliquot, pipette mixed, and boiled at 100°C for 4 min. 4 μg (dry weight) of venom was then added to the primary aliquot of fibrinogen (amounting to 0.1 mg/ml of venom and 1 mg/ml of fibrinogen in 40 μl total volume), pipette mixed, and immediately returned to the incubator. At each incubation time period (1 min, 5 min, 20 min, and 60 min), 10 μl was taken from the primary aliquot, added to a secondary aliquot, pipette mixed, and boiled at 100°C for 4 min. The secondary aliquots were then loaded into the gels and run in 1× gel running buffer at room temperature for 20 min at 90 V (Mini Protean3 power-pack from Bio-Rad, Hercules, CA, USA) and then 120 V until the dye front neared the bottom of the gel. Gels were stained with colloidal coomassie brilliant blue G250 (34% methanol (VWR Chemicals, Tingalpa, QLD, Australia), 3% orthophosphoric acid (Merck, Darmstadt, Germany), 170 g/l ammonium sulfate (Bio-Rad, Hercules, CA, USA), 1 g/l coomassie blue G250 (Bio-Rad, Hercules, CA, USA)), and destained in deionised H 2 O.
To quantify the band intensities in the gels, scanned gel images were uploaded to ImageJ (Version 1. 4.3.67, NIH, 2006) . Gel images were converted to black and white and adjusted for brightness and contrast. Using the rectangular tool, control bands were selected and defined as the first lane. Subsequent bands comprising of venom treatments with incubations of 1, 10, 20, 30, 40, 50 and 60 min were defined as lanes 2-8. Selected bands were then plotted, and each peak was isolated using the line-drawing function by drawing vertical lines down from the center of each trough. Using the wand function, band-intensity values were automatically produced by clicking on isolated peaks. These values were then exported to Excel, where the degradation of fibrinogen chains was calculated as proportions of the control.
Cleavage of fluorescent substrates
Fluorescent substrate cleavage studies were conducted as previously described by us (Cipriani et al., 2017; Debono et al., 2017; Dobson et al., 2017; Koludarov et al., 2017) . A working stock solution of freezedried venom was reconstituted in a buffer containing 50% deionised H 2 O/50% glycerol (> 99.9%, Sigma) at a 1:1 ratio to preserve enzymatic activity and reduce enzyme degradation with the final venom concentration of 0.1 mg/ml, and then stored at −20°C. For assessing the PLA 2 activity a fluorescence substrate assay (EnzChek ® Phospholipase A 2 Assay Kit, ThermoFisher Scientific). A working stock solution of freeze dried venom was reconstituted in a buffer containing 50% deionised H 2 O/50% glycerol (99.9%, Sigma) at a 1:1 ratio to preserve enzymatic activity and reduce enzyme degradation with the final venom concentration of 0.1 mg/ml, and then stored at −20°C. Venom solution (0.1 μg in dry venom weight) was brought up to 12.5 μl in PLA 2 reaction buffer (250 mM Tris-HCL, 500 mM NaCl, 5 mM CaCl 2 , pH 8.9) and plated out in triplicates on a 384 well plate. Triplicates were measured by adding 12.5 μl quenched 1 mM EnzChek ® Phospholipase A 2 substrate per well (total volume 25 μl/well) over 100 cycles at an excitation of 485 nm and emission of 520 nm, using a Fluoroskan Ascent (ThermoFisher Scientific). The negative control consisted of PLA 2 reaction buffer and substrate only. For testing on RDES substrates (Fluorogenic Peptide Substrate, R & D systems Cat#s ES001, ES002, ES005 AND ES0011, Minneapolis, Minnesota), 10ul of 0.01 μg/μl venom stock was plated in triplicate on a 384-well black plate and measured by adding 90 μl quenched fluorescent substrate per well. The substrate concentration was 10 μl of each substrate stock solution dissolved into 4.990 ml of enzyme buffer (150 mM NaCl and 50 mM Tri-HCl pH 7.4). Fluorescence was monitored over 400 min or until activity ceased. Excitation was at 320 nm and emission was at 405 nm for substrates ES001, ES002 and ES005. Excitation was at 390 nm and emission was at 460 nm for substrate ES011. The machine was programmed to shake the plate for three sec before each reading to maintain homogeneity in the wells.
Statistical analyses
All variables were measured in triplicate for each sample and the mean values for each sample were used to test for Pearson's correlations between antivenom efficacy, clotting time, CAT, TEG, factor X activation, activity on Substrate 2, and cleavage of each fibrinogen chain. We note that some may argue for a non-parameteric equivalent such as Spearman's rank correlation due to the small sample sizes (N = 6 for all correlations except for antivenom vs clotting time which is N = 4), but variables passed a Shapiro-Wilks test of normality (unsurprisingly due to the small samples and low power of this test) and, more importantly, we were interested in the actual values of the variables rather than their ranks. Nevertheless, we note that Spearman's rank correlations give qualitatively similar or identical results to the Pearson's correlations we report herein.
Results
Coagulation analyses and relative antivenom efficacy
To evaluate pro-or anticoagulation activities, assessment was carried out on an automated viscosity-based (mechanical) detection system analyzer (Stago STA-R Max) that measures clotting times with a maximum reading time of 999 s -the analyzer's limit. There was significant variation between samples in the ability to clot plasma, with times to clot (in sec) at the maximum venom concentration tested (20 μg/ml) being: SP01 (19.1 ± 0.20 s), SP02 (100 ± 4.76 s), SP03 (537.13 ± 16.06 s), SP04 (50.03 ± 1.59 s), SP05 (23.77 ± 0.49 s), and SP06 (379.50 ± 16.96 s) (Fig. 1) . Only SP03 did not significantly differ relative to the spontaneous clotting time of this batch of recalcified plasma (556.33 ± 29.92 s). The actions were shown to be calcium-dependent, with the complete abolition of activity in the absence of calcium. The relative presence of phospholipid was also a driving factor but to a much less extent, with the venoms clotting slower in the absence of phospholipid by a ratio of: 1.9 (SP01), 1.7 (SP02), 1.7 (SP04), and 1.8 (SP05).
In addition to clotting ability varying significantly between the specimens, antivenom efficacy also varied moderately between samples (Fig. 1) . Testing on SP01 revealed that the boomslang antivenom (8.55 ± 1.2 times shift in clotting curve) was much more effective than the polyvalent (3.2 ± 0.09 times shift in clotting curve) or saw-scaled viper (1.84 ± 0.01 times shift in clotting curve). Therefore, for the other species boomslang antivenom was tested, with relative clotting curve shifts of: SP02 (21.78 ± 0.89 times shift in clotting curve); SP04 (21.98 ± 0.45 times shift in clotting curve); and SP05 (12.03 ± 0.12 times shift in clotting curve). These values are independent of relative venom potency, as they reflect the proportional shift of a clotting curve by the antivenom. While there was not a significant statistical correlation between clotting time and antivenom efficacy (r = 0.820, t = 2.024, df = 2, P = 0.180), the sample size was N = 4, which limited our ability to conclusively demonstrate this effect, despite the high estimated correlation coefficient (r = 0.82). Thus, that the boomslang antivenom was able to proportionally shift the clotting curve more for the two more moderately potent venoms (SP02 and SP04) than to the two more potent venoms (SP01 and SP05) is therefore suggestive that the differences in surface chemistry driving clotting activity are key sites that also guide relative antivenom efficacy.
Calibrated automated thromography (CAT)
To evaluate the ability to generate endogenous thrombin in plasma samples, assessment was carried out on a Fluoroskan Ascent fluorometer with the CAT (calibrated automated thrombography) function. The venoms showed significant diversity in the ability to produce thrombin (Fig. 2) , with SP01 and SP05 being the most potent. We found a very strong correlation between CAT and clotting time (r = 0.912, t = 4.444, df = 4, P = 0.011).
Zymogen activation: Factor X and prothrombin
To evaluate the ability to activate the zymogens Factor X and prothrombin, assessment was carried out on a Fluoroskan Ascent fluorometer. Zymogen testing revealed that the clotting action (Fig. 1 ) and thrombin production (Fig. 2) was not due to activation of prothrombin but was due to the activation of Factor X (Fig. 3) . Consistent with the clotting times and CAT patterns, the most potent were SP01, SP04 and SP05. While we were unable to demonstrate a direct correlation Fig. 1 . Clotting times, coagulation dose-response curve and normalised logarithmic transformed views for effects upon recalcified plasma. Red curve lines represent venom in optimal conditions (i.e. with calcium and phospholipid) while other curve colours represent the clotting activity remaining after 2 min preincubation of venom with an antivenom and then the same dilution series were run as for the red line protocol. The antivenom remained a constant in the second protocol while the venom was diluted against it as per the curve graph x-axis concentrations (μg/ml). The curve graph y-axis is time (sec). Normalised logarithmic graph x-axis is log concentration (μg/ml) and y-axis is normalised time (%). Values are means from N = 3. Standard deviation bars are shown for each data point, although for most points the error bars are smaller than the dot point. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) Fig. 2 . Calibrated Automated Thrombogram curves for 0.083 μg/ml venom concentration on human plasma. X-axis is time (sec) and y-axis is nM of thrombin production. Values are N = 3. Fig. 3 . Relative ability to activate Factor X. Values are N = 3. Toxicology Letters 288 (2018) 119-128 between Factor X activation and CAT (r = −0.694, t = −1.931, df = 4, P = 0.126) or Factor X activation and CAT (r = −0.551, t = −1.320, df = 4, P = 0.258), this may be a result of low sample size given the reasonably high estimated correlation coefficient. The correlation coefficient is a negative value because a higher level of Factor X activity would produce quick CAT and clotting times. This discordance between correlation coefficient and other statistical values would have been strongly influenced in the Factor X activation assay by SP05 being disproportionately more potent than SP01 and SP04, in contrast to the clotting and thrombin generation assays where SP01 and SP05 did not vary significantly (Figs. 1 and 2 ). This variance in relative patterns may be explained by the clotting and thrombin assays being run in plasma and thus additional interactions and dynamics coming into play beyond that of simple Factor X activation as assayed in this test.
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Thromboelastography
To evaluate the strength of plasma clots formed by procoagulant mechanisms, assessment was undertaken using a Thromboelastograph (TEG) viscoelastic hemostatic assay, where strength of the clot is measured as the maximum amplitude of a clotting curve (i.e. thrombus velocity curve) in millimeters. TEG analyses of venom effects upon plasma showed that all venoms were able to form strong, stable clots ( Fig. 4A ) consistent with their relative plasma clotting times (Fig. 1) , CAT effects (Fig. 2 ) and in line with the ability to activate Factor X (Fig. 3) . Relative to the time to spontaneous clotting exhibited by recalcified plasma, the venoms were faster by ratios of: SP01 (21.80), SP02 (3.02), SP03 (1.11), SP04 (8.23), SP05 (12.67), AND SP06 (1.56). Only SP03 did not differ significantly from the control, which was also consistent with the negligible effects upon clotting time (Fig. 1) , CAT ( Fig. 2) and Factor X activation (Fig. 3) results. TEG plasma testing was strongly and positively correlated with both clotting time (r = 0.983, t = 10.696, df = 4, P = 0.0004) and CAT (r = 0.835, t = 3.040, df = 4, P = 0.038), but in contrast we found no evidence of a correlation between TEG and Factor X activation (r = −0.486, t = −1.028, df = 4, P = 0.362) due to the disproportionate effect SP05 had in the Factor X activation assay.
Thromboelastography analyses of direct effects upon fibrinogen showed that only SP01 and SP05 were also able to cleave fibrinogen to form clots of about 50% the strength of those formed by thrombin (Fig. 4B) . None of the other venoms were able to clot or degrade fibrinogen in such a way that thrombin added after 30 min formed other than a normal size and strength clot (Fig. 4C) .
Cleavage of fibrinogen
To quantify the cleavage of the fibrinogen chains (Aα, Bβ and γ), 1D reduced PAGE gels were performed for fibrinogen samples which had been incubated with venom. Extreme diversity between the specimens was evident in the relative speed of cleavage of Aα and Bβ chain cleavage (Fig. 5) , with SP05 being the most potent in this regard, but with none of the venoms cleaving the gamma chain. Normalised potency values for the Aα chain cleavage activity were SP01 (0.90 ± 0.2), SP02 (0.171 ± 0.12), SP03 (0.197 ± 0.03), SP04 (0.54 ± 0.02), SP05 (0.99 ± 00.01), and SP06 (0.55 ± 0.01) while normalised potency values for the Bβ chain cleavage activity were SP01 (0.32 ± 0.07), SP02 (0.14 ± 0.09), SP03 (0.08 ± 0.02), SP04 (0.15 ± 0.02), SP05 (0.98 ± 0.02), and SP06 (0.39 ± 0.03). Activity 
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Toxicology Letters 288 (2018) 119-128 on substrate ES002 was strongly positively correlated with the ability to degrade both the Aα (r = 0.829, t = 2.968, df = 4, P = 0.041) and Bβ (r = 0.807, t = 2.731, df = 4, P = 0.052) chains of fibrinogen. Note that the correlation is significant for the alpha chain and marginally non-significant in the beta chain, though the latter is likely a consequence of the small sample size as the correlation coefficient is strong (r > 0.7). The ability to degrade the alpha and beta chains of fibrinogen was also strongly positively correlated with each other (r = 0.786, t = 2.544, df = 4, P = 0.064).
Cleavage of fluorescent substrates
To assess enzymatic activities, a Fluoroskan Ascent fluorometer and fluorescent substrates known to be cleaved by metalloprotease, serine protease and phospholipase A 2 enzymes were used as proxy indicators for the presence of certain toxin classes. There was a tremendous functional diversity within the venoms (Fig. 6 ). There was no taxonomical pattern between the species according to enzymatic activity in relation to species designation or confirmed geographical origins.
Discussion
The Atractaspis venoms displayed the ability to clot plasma (Fig. 1) due to thrombin generation (Fig. 2) as a result of Factor X activation (Fig. 3) , resulting in the formation of strong clots in plasma (Fig. 4) . The cofactor dependency was absolute in regards to calcium, with all venoms displaying no activity in the absence of calcium, while tests performed in the absence of phospholipid displayed almost half the activity. While SP01 and SP05 were also shown to directly clot fibrinogen (Fig. 4B) , the speed of action was much slower than that of the thrombin-generation driven clotting and thus would not be likely to contribute to envenomation effects. The other species neither directly clotted fibrinogen (Fig. 4B ) nor degraded it to such an extent that thrombin was not able to form a strong, stable clot from the venomtreated fibrinogen (Fig. 4C) . Consistent with this, SP01 and SP05 were most potent in the fibrinogen gel analyses (Fig. 5) .
The relative potency of SP01 and SP05 were on par with that of snakes characterized as having lethal levels of thrombin-generation ability such as saw-scaled vipers (Echis species) (Rogalski et al., 2017) . In addition to risk from bites in the wild, specimens from the Atractaspis genus are regularly imported into the exotic pet trade and thus are a source of exotic snakebite in the developed world. Therefore, the potent procoagulant action revealed in this study is cause for concern.
In this study, the ability of available African antivenoms to neutralize the venoms varied, with the SAVP boomslang antivenom being the most relatively effective. While the level of efficacy of the best neutralized species was less than half that of the target species Dispholidus typus , the most potent species were neutralized at a relative level of less than seven times that of D. typus efficacy levels and on par with the poorly neutralized Thelatornis 
B. Oulion et al.
Toxicology Letters 288 (2018) 119-128 mossambicus . This suggests that, while the SAVP boomslang antivenom does neutralize the coagulotoxic effects of Atractaspis venoms, the efficacy levels indicate that impractical, large amounts of antivenom would be required. In contrast, as the SAVP polyvalent and saw-scaled antivenoms performed comparatively poorly, even under the idealized testing regime in this study, it is very unlikely they would have any significant clinical efficacy. The protocols used in this study to characterize coagulation effects, cofactor dependency and antivenom efficacy have been previously validated on diverse genera ranging from colubrids (Dispholidus and Thelatornis) , elapids (Hoplocephalus, Notechis, Paroplocephalus and Tropidechis) and viperids (Echis) (Rogalski et al., 2017) . These protocols have been shown to be more precise in characterizing the potency and specificity of the coagulation functions than historical WHO protocols incorporating the MCD (minimum coagulant dose) method (Theakston and Reid, 1983) .
Similarly, the antivenom testing protocol utilized in this study provides a more accurate estimation of antivenom neutralization ability than the previous WHO methods. Our new method prioritizes rapid, high-affinity antibody-toxin interactions more reflective of real-world scenarios Lister et al., 2017; Rogalski et al., 2017) . In contrast, the traditional WHO protocol uses prolonged incubation times and thus may overestimate efficacy (Segura et al., 2010; WHO, 1981 WHO, , 2010a , particularly for coagulotoxic venoms which readily degrade. This was shown by us in our study of Echis venoms which showed a much narrower taxonomic spectrum of efficacy for the ICP EchiTab-Plus-ICP antivenom (Rogalski et al., 2017) than that which it had been attributed to through the use of the WHO prolonged-incubation protocol (Segura et al., 2010) . Indeed, Vargas et al. (2011) observed significant loss of coagulant ability in Oxyuranus venoms incubated for 30 min compared to 3 min. Thromboelastography in this study was able to discriminate between procoagulant (Fig. 4A ) and pseudo-procoagulant (Fig. 4B) effects. This method, and the thromboelastometry modification, are becoming increasingly important in snake venom research for such studies due to the ability to determine clot strength and accurately quantify specific effects upon clotting (Dambisya et al., 1994 (Dambisya et al., , 1995 Hiremath et al., 2016; Jackson et al., 2016; Nagel et al., 2014; Nielsen, 2018; Nielsen and Bazzell, 2017; Nielsen and Boyer, 2016; Nielsen et al., 2017a Nielsen et al., ,b, 2016 Nielsen et al., , 2018 Oguiura et al., 2014; Strydom et al., 2016) .
Calibrated automated thrombography has also been shown to be useful in determining the ability of venoms to generate thrombin (Isbister et al., 2010; Lister et al., 2017) . In this study, the venoms were shown to have similar activity levels (i.e. areas under the curve) but with different initiation times and slopes to peak formation (Fig. 2) . The nature of the enzymatic actions responsible for these differences should be the subject of future work.
While it was beyond the scope of this study to determine the specific toxin type responsible for the Factor X activation, the cross-reactivity of the Atractaspis venoms with SAVP boomslang antivenom suggests that Toxicology Letters 288 (2018) 119-128 metalloprotease toxins are the responsible agents due to the wellcharacterized nature of boomslang venom as dominated by coagulotoxic P-III type snake venom metalloproteases (SVMP) Kamiguti et al., 2000; Pla et al., 2017) . Factor X activating SVMP have been previously only ever characterized from Bothrops, Daboia, Echis and Macrovipera viperid venoms Hofmann and Bon, 1987; Kisiel et al., 1976; Siigur et al., 2004; Takeya et al., 1992) . All Factor X activating SVMP are coupled to a pair of lectin chains (thus are P-IIId SVMP) and are calcium dependent (Morita, 1998) . Factor X activation has also been reported for calcium-dependent kallikrein-type serine proteases from Bungarus and Ophiophagus elapid venoms and Cerastes viperid venoms (Morita, 1998; Vaiyapuri et al., 2015) . However, the relative levels or potency of the Factor X activating kallikrein-type serine proteases in Bungarus, Ophiophagus and Cerastes venoms suggests that they play little, if any, role in prey capture or the development of clinical pathologies in those venoms. The ability to cleave fibrinogen in a thrombin-like, pseudo-procoagulant manner to form weak, unstable clots (Fig. 4B) is well-characterized in viperid venoms (with some suggestion of this activity also present in elapid venoms such as Micrurus) and in viper venoms has been shown to be due to kallikrein-type serine proteases (Vaiyapuri et al., 2015) . In contrast, the ability to degrade fibrinogen in a nonclotting manner (Fig. 5 ) has been widely observed for SVMP in snakes and for kallikrein-type serine proteases in lizard and snake venoms (Hendon and Tu, 1981; Koludarov et al., 2017; Vaiyapuri et al., 2015) .
While fibrinogen clotting cleavage has been reported for only kallikrein-type serine proteases, it remains to be elucidated in Atractaspis venoms which toxin type is responsible for this function. This should be the subject of future work, just as such efforts should be undertaken to confirm SVMPs are responsible for the Factor X activation activity in these enigmatic and rare venoms. In addition, DNA typing of specimens should be undertaken in order to conclusively link taxonomy with toxinology in these species which are notoriously hard to identify using only external features such as scalation patterns.
In conclusion, this study reveals previously unknown and extreme potent coagulotoxic actions in the Atractaspis genus and thus provides information to guide clinicians. Importantly, our results suggest limited management options in treating Atractaspis envenomations due to poor antivenom neutralization capacity.
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